0001209191-21-023657.txt : 20210330
0001209191-21-023657.hdr.sgml : 20210330
20210330201627
ACCESSION NUMBER: 0001209191-21-023657
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210326
FILED AS OF DATE: 20210330
DATE AS OF CHANGE: 20210330
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DARCY THOMAS E
CENTRAL INDEX KEY: 0001126910
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51531
FILM NUMBER: 21789254
MAIL ADDRESS:
STREET 1: C/O SCIENCE APPLICATIONS INTL CORP
STREET 2: 10260 CAMPUS POINT DR.
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viracta Therapeutics, Inc.
CENTRAL INDEX KEY: 0001061027
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943295878
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2533 S COAST HWY 101
STREET 2: SUITE 210
CITY: CARDIFF
STATE: CA
ZIP: 92007
BUSINESS PHONE: 858-400-8470
MAIL ADDRESS:
STREET 1: 2533 S COAST HWY 101
STREET 2: SUITE 210
CITY: CARDIFF
STATE: CA
ZIP: 92007
FORMER COMPANY:
FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19980709
FORMER COMPANY:
FORMER CONFORMED NAME: SUNESIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19980501
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-26
0
0001061027
Viracta Therapeutics, Inc.
VIRX
0001126910
DARCY THOMAS E
C/O VIRACTA THERAPEUTICS, INC.
2533 S COAST HWY 101, SUITE 210
CARDIFF
CA
92007
1
0
0
0
Stock Option (Right to Buy)
8.74
2021-03-26
4
A
0
80000
0.00
A
2031-03-26
Common Stock
80000
80000
D
One thirty-sixth (1/36th) of the Shares subject to the Option shall vest on the one (1) month anniversary of March 1, 2021 (the "Vesting Commencement Date"), and one thirty-sixth (1/36th) of the Shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Therapeutics, Inc. 2021 Equity Incentive Plan) through each such date.
/s/ Michael Mueller, as Attorney-in-Fact
2021-03-30